Identification of a putative protein profile associating with tamoxifen therapy resistance in breast cancer
Tamoxifen-resistance is a major cause of death in patients with recurrent breast cancer. Current clinical factors can correctly predict therapy response in only half of the treated patients. Identification of proteins that associate with tamoxifen-resistance is a first step towards better response prediction and tailored treatment of patients. In the present study we intended to identify putative protein biomarkers indicative of tamoxifen therapy-resistance in breast cancer, using nanoLC coupled with FTICR MS. Comparative proteome analysis was performed on ~5,500 pooled tumor cells (corresponding to ~550 ng protein lysate/analysis) obtained through laser capture microdissection (LCM) from two independently processed data sets (n=24 and n=27) containing both tamoxifen therapy-sensitive and therapy-resistant tumors. Peptides and proteins were identified by matching mass and elution time of newly acquired LC-MS features to information in previously generated accurate mass and time tag (AMT) reference databases.
- Research Organization:
- Pacific Northwest National Lab. (PNNL), Richland, WA (United States). Environmental Molecular Sciences Lab. (EMSL)
- Sponsoring Organization:
- USDOE
- DOE Contract Number:
- AC05-76RL01830
- OSTI ID:
- 958474
- Report Number(s):
- PNNL-SA-63534; 7190a; KP1704020; TRN: US201002%%165
- Journal Information:
- Molecular & Cellular Proteomics. MCP, 8(6):1278-1294, Vol. 8, Issue 6
- Country of Publication:
- United States
- Language:
- English
Similar Records
High-throughput proteomics of breast carcinoma cells: a focus on FTICR-MS
A novel approach to the study of the functional proteome in breast cancer